Cargando…

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression

The effectiveness of the esketamine nasal spray (ESK-NS) for treatment-resistant depression (TRD) has been confirmed by real-world studies. Available evidence derived from clinician-rated assessments might differ from patients’ perceptions about the helpfulness of treatments. We aimed to verify the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pepe, Maria, Bartolucci, Giovanni, Marcelli, Ilaria, Pesaresi, Francesco, Brugnami, Andrea, Caso, Romina, Fischetti, Alessia, Grisoni, Flavia, Mazza, Marianna, Camardese, Giovanni, Di Nicola, Marco, Sani, Gabriele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604956/ https://www.ncbi.nlm.nih.gov/pubmed/37891860 http://dx.doi.org/10.3390/brainsci13101494

Ejemplares similares

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
por: Capuzzi, Enrico, et al.
Publicado: (2021)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
por: Carter, Maximilian, et al.
Publicado: (2022)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Intranasal esketamine as therapeutic option: a case report of an adolescent with treatment resistant depression
por: Skala, Katrin, et al.
Publicado: (2023)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
por: Dijkstra, Francis M, et al.
Publicado: (2022)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report
por: Olivola, Miriam, et al.
Publicado: (2022)

Intranasal esketamine use in bipolar disorder: A case report
por: Skriptshak, Courtney, et al.
Publicado: (2021)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
por: Wang, Sheng-Min, et al.
Publicado: (2021)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Median effective dose of esketamine for intranasal premedication in children with congenital heart disease
por: Huang, Jiajia, et al.
Publicado: (2023)

A Comparison of Intranasal Dexmedetomidine, Esketamine or a Dexmedetomidine-Esketamine Combination for Induction of Anaesthesia in Children: A Randomized Controlled Double-Blind Trial
por: Lu, Xinlei, et al.
Publicado: (2022)

The Nrf2 Pathway in Depressive Disorders: A Systematic Review of Animal and Human Studies
por: Sani, Gabriele, et al.
Publicado: (2023)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
por: Keeler, Johanna Louise, et al.
Publicado: (2023)

Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series
por: Mazza, Marianna, et al.
Publicado: (2022)

Psychopathological Features of Bipolar Depression: Italian Validation of the Bipolar Depression Rating Scale (I-BDRS)
por: Bruschi, Angelo, et al.
Publicado: (2018)

Intranasal Esketamine and Current Suicidal Ideation With Intent in Major Depression Disorder: Beat the Clock, Save a Life, Start a Strategy
por: Pompili, Maurizio
Publicado: (2020)

Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
por: Marcatili, Matteo, et al.
Publicado: (2022)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
por: Rothärmel, Maud, et al.
Publicado: (2022)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

Intranasal esketamine combined with oral midazolam provides adequate sedation for outpatient pediatric dental procedures: a prospective cohort study
por: Wang, Jing, et al.
Publicado: (2023)

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study
por: Takahashi, Nagahide, et al.
Publicado: (2021)

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
por: Rognoni, Carla, et al.
Publicado: (2023)

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
por: Vasiliu, Octavian
Publicado: (2023)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
por: Faisant, S., et al.
Publicado: (2022)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis
por: Chen, Cheng-Chuan, et al.
Publicado: (2023)

Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
por: Gutierrez, Gilmar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hlospa0jrk1sif0q3t89l561tv